| 1 |
Martin de Miguel I, Cruz-Utrilla A, Oliver E, Escribano-Subias P. Novel Molecular Mechanisms Involved in the Medical Treatment of Pulmonary Arterial Hypertension. Int J Mol Sci 2023;24. [PMID: 36835558 DOI: 10.3390/ijms24044147] [Reference Citation Analysis]
|
| 2 |
Santos-gomes J, Gandra I, Adão R, Perros F, Brás-silva C. An Overview of Circulating Pulmonary Arterial Hypertension Biomarkers. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.924873] [Reference Citation Analysis]
|
| 3 |
Chelladurai P, Kuenne C, Bourgeois A, Günther S, Valasarajan C, Cherian AV, Rottier RJ, Romanet C, Weigert A, Boucherat O, Eichstaedt CA, Ruppert C, Guenther A, Braun T, Looso M, Savai R, Seeger W, Bauer UM, Bonnet S, Pullamsetti SS. Epigenetic reactivation of transcriptional programs orchestrating fetal lung development in human pulmonary hypertension. Sci Transl Med 2022;14:eabe5407. [PMID: 35675437 DOI: 10.1126/scitranslmed.abe5407] [Reference Citation Analysis]
|
| 4 |
Hajra A, Safiriyu I, Balasubramanian P, Gupta R, Chowdhury S, Prasad AJ, Kumar A, Kumar D, Khan B, Bilberry RS, Sarkar A, Malik P, Aronow WS. Recent Advances and Future Prospects of Treatment of Pulmonary Hypertension. Current Problems in Cardiology 2022. [DOI: 10.1016/j.cpcardiol.2022.101236] [Reference Citation Analysis]
|
| 5 |
Razavi BM, Hosseinzadeh H. Pulmonary Hypertension. Comprehensive Pharmacology 2022. [DOI: 10.1016/b978-0-12-820472-6.00130-4] [Reference Citation Analysis]
|
| 6 |
Chen Y, Cui L, Wang C, Liu J, Guo J. Ameliorative Effects and Mechanism of Buyang Huanwu Decoction on Pulmonary Vascular Remodeling: Network and Experimental Analyses. Oxid Med Cell Longev 2021;2021:4576071. [PMID: 34422208 DOI: 10.1155/2021/4576071] [Reference Citation Analysis]
|
| 7 |
Montagnoli TL, da Silva JS, Sudo SZ, Santos AD, Gomide GF, de Sá MPL, Zapata-Sudo G. ROCK Inhibition as Potential Target for Treatment of Pulmonary Hypertension. Cells 2021;10. [PMID: 34209333 DOI: 10.3390/cells10071648] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 8 |
Lopez-Crisosto C, Arias-Carrasco R, Sepulveda P, Garrido-Olivares L, Maracaja-Coutinho V, Verdejo HE, Castro PF, Lavandero S. Novel molecular insights and public omics data in pulmonary hypertension. Biochim Biophys Acta Mol Basis Dis 2021;1867:166200. [PMID: 34144090 DOI: 10.1016/j.bbadis.2021.166200] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Bäz L, Roßberg M, Grün K, Kretzschmar D, Berndt A, Schulze PC, Jung C, Franz M. Serum Liberation of Fetal Fibronectin Variants in Patients with Pulmonary Hypertension: ED-A+ Fn as Promising Novel Biomarker of Pulmonary Vascular and Right Ventricular Myocardial Remodeling. J Clin Med 2021;10:2559. [PMID: 34207881 DOI: 10.3390/jcm10122559] [Reference Citation Analysis]
|
| 10 |
Adefegha SA, Molehin OR, Fakayode AE. Targeting Molecular and Cellular Mechanisms in Pulmonary Hypertension. Targeting Cellular Signalling Pathways in Lung Diseases 2021. [DOI: 10.1007/978-981-33-6827-9_17] [Reference Citation Analysis]
|
| 11 |
Sharma M, Singh TU, Lingaraju MC, Parida S. Potential Cellular Targets Associated with the Signaling of the Pulmonary Hypertension. Targeting Cellular Signalling Pathways in Lung Diseases 2021. [DOI: 10.1007/978-981-33-6827-9_19] [Reference Citation Analysis]
|
| 12 |
Kocken JMM, da Costa Martins PA. Epigenetic Regulation of Pulmonary Arterial Hypertension-Induced Vascular and Right Ventricular Remodeling: New Opportunities? Int J Mol Sci 2020;21:E8901. [PMID: 33255338 DOI: 10.3390/ijms21238901] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
|
